Results of these studies showed that galectin-1, -3, and -13 are significantly dysregulated in the placentas of GDM patients, and galectin-13 has recently been tested as a potential biomarker for GDM-screening [43,44,45,46]. Here, LGALS1 is linked to gestational diabetes.